VRDN FY 2023 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$314,000-82.3% YoY

Gross Profit

$314,000100.0% margin

Operating Income

-$254M-81035.0% margin

Net Income

-$238M-75711.5% margin

EPS (Diluted)

$-5.31

Cash Flow

Operating Cash Flow

-$184M

Free Cash Flow

-$185M

Stock-Based Comp.

$67M

Balance Sheet

Total Assets

$490M

Total Liabilities

$48M

Stockholders' Equity

$442M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$314,000	$2M	-82.3%
Gross Profit	$314,000	$2M	-82.3%
Operating Income	-$254M	-$134M	-89.5%
Net Income	-$238M	-$130M	-83.0%